Nabriva Therapeutics (NBRV) took a big risk pushing its novel antibiotic, lefamulin, into a late-stage clinical trial in patients with hospital-acquired pneumonia without any prior clinical data. On Monday, the bet paid off.
The Ireland-based company said lefamulin achieved the primary and secondary endpoints in a phase 3 study of 551 patients with community-acquired bacterial pneumonia. This is the first of two phase 3 clinical trials needed to seek regulatory approval for lefamulin. The second study will read out results in the fourth quarter.
Nabriva shares more than doubled to $14.40 in pre-market trading. The stock closed Friday at $6.96.
About the Author Reprints
